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Summary Ret/PTC oncogene has been described with a frequency of 2.5-30% in papillary thyroid carcinomas. We examined the expression
of ret/PTC in 99 German papillary thyroid carcinomas, including two recently described new variants of ret/PTC3 and identified eight ret/PTC-
positive tumours (8%) but none with the new variants.
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Papillary thyroid carcinoma (PTC) is the most common thyroid
cancer, accounting for 50-70% of all thyroid malignancies. Most
of these tumours have a rather benign clinical course and cure can
often be achieved. A subset of these tumours, however, shows a
more aggressive behaviour with nodal metastasis, local recurrence,
distant spread and shortened life span. Attempts to identify prog-
nostic markers have been made on the basis of patient
characteristics, tumour stage, histological appearance and genetic
changes in these tumours (Nikiforov and Fagin, 1997).
One of the most extensively studied genes in this respect is the
ret proto-oncogene, a receptor tyrosine kinase associated with the
receptor for glial cell line-derived neurotrophic factor (GDNF)
(Jing et al, 1996). Targeted disruption of ret and GDNF have
shown a pivotal role of each molecule in cellular differentiation
and proliferation (Schuchardt et al, 1995; Moore et al, 1996;
Pichel et al, 1996; Sanchez et al, 1996).
This has been exemplified in multiple endocrine neoplasia type
II, in which activating point mutations of ret represent the under-
lying cause ofthe disease, leading to medullary thyroid carcinoma
(Mulligan et al, 1993; Xing et al, 1996). In thyrocytes, another
alteration of ret, chimerical proteins named ret/PTC generated by
chromosomal translocation, may cause papillary thyroid carci-
noma. The 3' tyrosine kinase domain ofret is fused to the 5' part of
the H4 (PTC1), Rla (PTC2) or elel (PTC3) gene, resulting in
constitutional expression of ret and phosphorylation of ret and
other target proteins (Grieco et al, 1990; Bongarzone et al, 1993;
Santoro et al, 1994). This event was specific for papillary thyroid
carcinoma (Santoro et al, 1993), but the reported frequencies
varied widely from 2.5% to 30% of these tumours (Santoro et al,
1992; Zou et al, 1994). The presence ofretIPTC in tumour tissue
has been suggested to be a potential marker for distant metastasis
and aggressive disease (Jhiang and Mazzaferri, 1994), even though
the biological consequences ofconstitutive ret expression in thyro-
cytes are largely undetermined. Only recently, targeted expression
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of ret/PTC1 in murine thyroid gland has been shown
to induce slowly progressive tumours, histologically resembling
papillary thyroid carcinoma (Jhiang et al, 1996; Santoro et al,
1996). However, recent results that related ret activation to clinical
follow-up found no association with adverse clinical outcome
(Sugg et al, 1996; Mayr et al, 1997).
Very recently, two new variants of ret/PTC3 (PTC4 and
ret/APTC3) have been described in radiation-induced tumours of
victims of Chernobyl (Fugazzola et al, 1996; Klugbauer et al,
1996), known to have a higher frequency of ret activation. This
raised the possibility that the frequency of ret activation may be
higher than that previously described and prompted us to examine
the expression of all five forms of ret/PTC known today in 99
German papillary thyroid tumours.
MATERIALS AND METHODS
We used tissue specimens of99 papillary thyroid carcinomas from
Hannover, Dusseldorf, Regensburg and Halle. Tissue (35-80 mg)
was homogenized in a rotor-stator device (Ultra-Turrax, IKA
Analysentechnik) under denaturing conditions, and total RNA was
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Figure 2 PCR results of all ret/PTC1- and ret/PTC3-positive patients. Lanes
1 and 11 show molecular weight marker pBR/Mspl, lane 2 the cell line TPC1
used as a positive control, lanes 3-9 PTC1 and lane 10 PTC3
extracted with the caesium chloride method or a commercial kit
(RNeasy, Qiagen). The integrity of the RNA was checked by gel
electrophoresis, and 5 jg oftotal RNA was reverse transcribed in a
20-gl volume with oligo-dT and reverse transcriptase (Supercript
II, Gibco) according to the manufacturer's instructions. For
polymerase chain reaction (PCR) 1 ,l of cDNA, 5 gl of buffer
(supplied with Taq polymerase), 0.5 pl of dNTP 20 mM each
(Pharmacia), 25 pmol of each primer, 0.5 gl of Taq polymerase
(USB) and water to 47 gl were mixed and heated to 80°C. The
reaction was started with 3 gl ofmagnesium chloride (25 mM) and
35 cycles of 30 s at 94°C, 15 s at 62°C and 15 s at 72°C were
carried out in a thermal cycler. The initial denaturation and final
extension were 5 min. Products were analysed by electrophoresis
in 2% agarose. Appropriate negative controls lacking cDNA were
always included, the cell line TPC-1 (Ishizaka et al, 1990) was
initially used to test PCR condition but was not included as a posi-
tive control in every reaction to minimize the chance ofcross-cont-
amination.
After a first round of screening with multiplex PCR using
primers PTC-1 (gtcggggggcattgtcat), PTC-2 (cagcaaggtgat-
gaagggga), PTC-3 (ctgcgccagaccatcacc) and ret-2 (cttcc-
gagggaattccca), positive results were independently confirmed in
two PCR reactions with primers ret2 or ret xl2R (gaccacttttc-
caaattcgcc) and the respective forward primer. For detection of
PTC3 variants, all cDNA samples were processed againusing only
primers PTC-3 and ret x12R. A schematical representation of the
expected product sizes and primer sites is shown in Figure 1.
Single-stranded DNA wasgeneratedby asymmetric PCR as above
withthe following modifications: 0.2 g1 ofPCRreaction volume was
used as the template, primerret xl2R was diluted 1:50 and50cycles
were performed. After purification over affinity columns (QiaQuick,
Qiagen) the templates were manually sequenced with Sequenase
(USB) according to the manufacturer's instructions using the diluted
ret xl2R and [a-35S]dATP (Amersham).
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Figure 3 Direct sequencing of PCR samples. Sample 1 is the ret/PTC3 sample, samples 2-5 are ret/PTC1 with tissue numbers and sample 6 is retVPTC1 from
the cell line TPC1. The fusion points are indicated, and the T to G mutations are marked with an asterisk
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Five microlitres of purified PCR samples (QiaQuick, Qiagen)
were digested with Tsp45I (New England Biolabs) and resolved in
2.5% agarose.
RESULTS
Seven ret/PTC1 (7%), no ret/PTC2, one ret/PTC3 transcript (1%),
no ret/PTC3a (PTC4), ret/PTC3b (ret/APTC3) or any other vari-
ants were identified in 99 papillary thyroid carcinomas and this
was confirmed by sequencing five of them (Figures 2 and 3). The
presence ofret/PTC2 cannot be excluded because ofthe lack of an
appropriate positive control, but our results are in concordance
with previous findings (Sugg et al, 1996).
Surprisingly, samples from patients 1, 2 and 3 showed a conser-
vative T to G mutation at position 333 ofthe H4 gene (Grieco et al,
1994), as described in the papillary thyroid carcinoma cell line
TPC-1 (Ishizaka et al, 1990) that we used as a positive control.
Contamination seems unlikely as repeated studies and use of
primer ret x12R, which would not amplify a contaminating PCR
product generated with primer ret-2, led to identical results. The
positive result for patient 1 was confirmed in a second tissue
sample from reoperation for local recurrence (results not shown).
The T to G mutation at position 333 of the H4 gene creates a
restriction site for Tsp45I. PCR products were analysed by Tsp45I
cleavage and consistently confirmed the sequence data, i.e. that
patients 1-3 have the TPC-1 mutation (results not shown).
DISCUSSION
Ret/PTC, although specific for papillary thyroid carcinoma
(Santoro et al, 1993), occurs in only a few cases of this most
common thyroid cancer.
Recently, new variants of ret/PTC3 have been found in post-
Chernobyl tumours (Fugazzola et al, 1996; Klugbauer et al, 1996),
which raised the possibility that the proportion ofret/PTC-positive
tumours might have been underestimated in the past, but the new
forms ret/PTC3a (ret/PTC4) and ret/PTC3b (ret/APTC3) did not
occur in our study population. No other variants of PTC1, -2 or -3
within the known breakpoint regions of the ret, H4, RIot and elel
genes could be detected. Variants resulting from breakpoints
outside these regions would not have been detectable with our
method. This strengthens the notion that variants ofret/PTC might
be specific to radiation-induced PTCs (Ito et al, 1993), as the
higher frequency of PTC3 itself seems to be related to radioactive
exposure (Fugazzola et al, 1995; Klugbauer et al, 1995).
Unexpectedly, three out of four sequenced PTC1 samples
showed a conservative T to G mutation at position 333 of the H4
gene six bases from the fusion point, without altering the amino
acid sequence. As technical reasons could be excluded with high
probability, a genetic polymorphism is the most likely explanation.
In our study population, the frequency of ret/PTC was low.
These results agree with those from Canadian patients (Sugg et al,
1996) but are at variance to a number of other studies reporting a
variable prevalence of up to 30% (Santoro et al, 1992; Zou et al,
1994; Bongarzone et al, 1996). Radiation appears not to be the
dominant factor for these differences. Our results in a region of
iodine deficiency, which compare well with data from iodine suffi-
cient areas, such as Canada (Sugg et al, 1996), argue against iodine
being an important influence. Differences may be attributable to
different detection methods, but Southern blotting, transfection
assays and reverse transcription polymerase chain reaction (RT-
PCR) have been reported to yield similar results (Bongarzone et al,
1996). Thus, the explanation ofthis variance remains elusive.
The prevalence of ret activation including unknown rearrange-
ments or overexpression appears to be higher (Williams et al,
1996). This may indicate that other forms ofret rearrangements are
still to be discovered or that, in contrast to normal follicular
thyroid cells (Fabien et al, 1992), wild-type ret mRNA is present in
malignant thyroid cells. If ret activation from any cause occurs at
high frequency, this marker may be useful in subtyping thyroid
cancer.
The low prevalence of ret/PTC, including the new forms as
shown in the present study, limits the possible prognostic role of
these rearrangements for thyroid carcinomas. As expression of
ret/PTC appears to alter the biological behaviour of thyrocytes,
factors in the ret signal transduction pathway are likely to play a
role in proliferation and differentiation of thyrocytes. These genes
can be considered candidate genes for thyroid carcinogenesis, and
clarification of their function may enhance the understanding of
this disease.
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